A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Verastem, Inc.
VSTM
$216M
Mkt Cap
$6.05
-2.10%
Verastem, Inc. (VSTM) has a 5-year average return on invested capital (ROIC) of -70.7%. This is below average and may indicate limited pricing power.
Verastem, Inc. (VSTM) has a market capitalization of $404M. It is classified as a small-cap stock.
Verastem, Inc. (VSTM) does not currently pay a regular dividend.
Verastem, Inc. (VSTM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Verastem, Inc. (VSTM) generated $-105 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Verastem, Inc. (VSTM) reported earnings per share (EPS) of $-3.66 in its most recent fiscal year.
Verastem, Inc. (VSTM) has a return on equity (ROE) of -917.4%. A negative ROE may indicate losses or negative equity.
Item 1. Business We are a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (“RAS”)/ mitogen activated pathway kinase (“MAPK”) pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. Our most advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to LGSOC, non-small cell lung cancer (“NSCLC”) and pancreatic cancer.
| Metric | TTM | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 89M | - |
| Net Income | -241M | -131M | -74M | -71M | -68M | -149M |
| EPS | $-4.28 | $-3.66 | $-4.57 | $-4.92 | $-5.28 | $-24.00 |
| Free Cash Flow | 0 | -105M | -64M | -54M | -34M | -139M |
| ROIC | -71.6% | -89.4% | -60.6% | -81.1% | -50.4% | -72.1% |
| Gross Margin | - | - | - | - | 99.1% | - |
| Debt/Equity | 0.00 | -1.41 | 0.52 | 0.00 | 0.17 | 4.89 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -160M | -115M | -73M | -61M | -49M | -132M |
| Operating Margin | 0.0% | - | - | - | -55.8% | - |
| ROE | 0.0% | -917.4% | -155.8% | -81.3% | -58.8% | -2079.9% |
| Shares Outstanding | 67M | 36M | 16M | 14M | 13M | 6M |
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | 89M | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | 99.1% | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -95M | -132M | -49M | -61M | -73M | -115M | -160M |
| Op. Margin | N/A | N/A | -55.8% | N/A | N/A | N/A | 0.0% |
| Net Income | -72M | -149M | -68M | -71M | -74M | -131M | -241M |
| Net Margin | N/A | N/A | -76.5% | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -50.4% | -72.1% | -50.4% | -81.1% | -60.6% | -89.4% | -71.6% |
| ROE | -58.3% | -2079.9% | -58.8% | -81.3% | -155.8% | -917.4% | 0.0% |
| ROA | -26.1% | -102.9% | -43.9% | -65.5% | -77.7% | -104.0% | -136.3% |
| Cash Flow | |||||||
| Op. Cash Flow | -75M | -139M | -34M | -54M | -64M | -105M | -133M |
| Free Cash Flow | -76M | -139M | -34M | -54M | -64M | -105M | 0 |
| Owner Earnings | -82M | -147M | -42M | -61M | -70M | -112M | -140M |
| CapEx | 1.5M | 7K | 33K | 196K | 0 | 28K | 0 |
| Maint. CapEx | 996K | 429K | 531K | 206K | 118K | 26K | 26K |
| Growth CapEx | 511K | 0 | 0 | 0 | N/A | 2K | 0 |
| D&A | 996K | 429K | 531K | 206K | 118K | 26K | 26K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 6.7M | 8.5M | 8.1M | 7.7M | 6.0M | 7.3M | 7.3M |
| Debt Repayment | 0 | 0 | 37M | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -110M | -8.4M | -49M | -21M | -50M | -48M | -60M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 138M |
| Long-Term Debt | 20M | 35M | 19M | 249K | 25M | 41M | 41M |
| Debt/Equity | 0.16 | 4.89 | 0.17 | 0.00 | 0.52 | -1.41 | 0.00 |
| Interest Coverage | -16.3 | -6.4 | -3.1 | -6.2 | -34.1 | -25.2 | -25.2 |
| Equity | 124M | 7.2M | 115M | 88M | 47M | -29M | -16M |
| Total Assets | 277M | 145M | 154M | 109M | 95M | 102M | 177M |
| Total Liabilities | 153M | 138M | 39M | 21M | 48M | 130M | 192M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -376M | -525M | -593M | -664M | -738M | -956M | -956M |
| Working Capital | 216M | 55M | 128M | 87M | 71M | 64M | 64M |
| Current Assets | 253M | 85M | 145M | 106M | 93M | 95M | 95M |
| Current Liabilities | 37M | 30M | 17M | 19M | 22M | 31M | 31M |
| Per Share Data | |||||||
| EPS | -16.44 | -24.00 | -5.28 | -4.92 | -4.57 | -3.66 | -4.28 |
| Owner EPS | -18.65 | -23.72 | -3.29 | -4.24 | -4.32 | -3.14 | -2.10 |
| Book Value | 28.21 | 1.15 | 8.99 | 6.05 | 2.93 | -0.81 | -0.23 |
| Cash Flow/Share | -16.91 | -22.28 | -2.61 | -3.70 | -3.94 | -2.94 | -3.61 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 4.4M | 6.2M | 12.8M | 14.5M | 16.2M | 35.7M | 66.8M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -1.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.5 | 14.6 | 3.0 | 4.2 | 1.4 | N/A | N/A |
| Price/Sales | N/A | N/A | 3.2 | N/A | N/A | N/A | N/A |
| FCF Yield | -41.0% | -132.6% | -9.6% | -14.6% | -96.6% | -79.1% | N/A |
| Market Cap | 186M | 104M | 348M | 368M | 66M | 132M | 404M |
| Avg. Price | 65.18 | 23.20 | 21.91 | 34.53 | 13.23 | 6.57 | 6.05 |
| Year-End Price | 42.12 | 16.80 | 27.12 | 25.44 | 4.08 | 3.71 | 6.05 |
Verastem, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 99.1%.
Verastem, Inc. (VSTM) has a 5-year average gross margin of 99.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Verastem, Inc. (VSTM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Verastem, Inc. (VSTM) has a book value per share of $-0.81, based on its most recent annual SEC filing.